Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

RELMADA THERAPEUTICS, INC. Director's Dealing 2020

Aug 19, 2020

34465_dirs_2020-08-19_d12dbf64-9c13-4a89-9389-4f267275f3ba.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2020-08-18

Reporting Person: Kelly Paul Edward (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-08-18 Common Stock M 22000 $3.24 Acquired 149121 Direct
2020-08-18 Common Stock F 1826 $39.03 Disposed 147295 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-08-18 Options to purchase common stock $3.24 M 22000 Disposed 2027-10-20 Common Stock (22000) Direct

Footnotes

F1: Reflects 1,826 shares withheld at the market price of $39.03 per share to fund the cashless exercise of 22,000 options owned by Mr. Kelly, which cashless exercise was approved in advance by the Board of Directors.

F2: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.